James Prudhomme

immunogenicity biologics cambridge healthtech institute drug delivery drug discovery clinical structure-based drug design bioassays diagnostics immuno-oncology clinical training phenotypic screening bioassay drug discovery technology pharma conference risk-based monitoring immunogenicity course immunotherapy cancer immunotherapy course companion diagnostics diagnostics conference clinical course clinical trial summit clinical trial conference phenotypic drug discovery 3d models drug screening immunogenicity risk immunogenicity testing fda biotherapeutics tissue models tissue engineering drug design protein engineering computational chemistry liquid biopsy point-of-care diagnostics oncology cancer patient recruitment precision medicine antibody assays tumor biology 3d cell culture cancer immunotherapy immunogenicity assessment point of care testing myeloma hematological malignancies hematological cancers quality by design clinical auditing tumor models immunogenicity conference antibody engineering protein therapeutics formulation strategies for biologics gpcr formulation assays pk/pd epigenetic targets computer-aided design biomarkers pharmaceutical bioinformatics chi conferences next generation dx summit drug-diagnostic early cancer surveillance cancer diagnostics tumor microenvironment lymphoid tissues inflammatory diseases mscs stromal cells stroma cells molecular diagnostics machine learning health-it cloud computing biotechnology doe design of experiments dna forensics molecular diagnotics digital medicine clinical trial optimization artificial intelligence pharma outsourcing outsourcing for clinical trials clinical trial immuno-oncology course bioassays course pharmaceuticals melanoma upper gi ovarian cancer breast cancer colorectal cancer lung cancer tumors hematologic cancers john hopkins sidney kimmel comprehensive cancer ce yale cancer center leukemia pharma training hematologic malignancies solid tumors big data for clinical trials clinical summit big data ich e6 addendum clinical quality management rbm clinical trials genomics central lab sourcing biomarker trials lab and diagnostics services clinical operations sample and biospecimen managmement pharmacokinetics antibodies biosimilars eczema inflammatory disease medical dermatology psoriasis acnea inflammatory skin diseases delivery technologies skin pharmacokinetics medical dermatology conference drug development in dermatology rosacea skin orphan skin disease skin cancer skin disease mechanisms dermatology antibody constructs bioassay course bioassay development drug lead optimization physiologically relevant assays 3d cell models immunotherapeutic approaches i/o drug discovery 3d culture cancer target cell-based models hca hcs/a phenotypic cell-based drug discovery high content analysis organ on-a-chip drug screening conference 3d tissue models stem-cell derived models pharmacology conference toxicology conference pharmacy cell-free dna dx poc leukemias lymphomas pharma course healthcare course medical course hematology clinical investigation clinical investigative sites clinical research clinical monitoring qbd clinical vendors clinical project management organotypic models drug r&d drug safety toxicology drug development screening for drugs in vitro cell models biological assay drug interference immune assay bioassay conference adcs drug injections pulmonary nasal spray oral delivery technology medical device oral drug oral delivery drug delivery technology nasal delivery peptide therapeutics admet nmr rational drug design regulatory affairs pharma biologics delivery student fellowships medicinal chemistry drug compounds gpcrs macrocyles sbdd nanomedicine nanotechnology novel constructs immunogencity phenotype biotechnology and pharmaceuticals screening molecule structural biology epigenetics physicochemical properties cabd kevin davies insight pharma reports genome chi sequencing assay development cancer drug tissue diagnostics exosomes microvesicles biomarkers congress biochemistry inhibitor kinase drug protein kinase chemistry